
Rachel S Knipe MD
Critical Care Medicine, Interstitial Lung Diseases
Instructor in Medicine, Massachusetts General Hospital
Join to view full profile
55 Fruit St.MGHBoston, MA 02114
Phone+1 617-726-5640
Dr. Knipe is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2010 - 2014
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2006
Certifications & Licensure
MA State Medical License 2010 - 2027
NY State Medical License 2008 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- ADAMTS14 is a Novel Modulator of Fibroblast Mechanoactivation in Pulmonary Fibrosis.Ingo Ganzleben, Alok Jaiswal, Yang Yang, Daniela M Santos, Alyce Segal
American Journal of Respiratory and Critical Care Medicine. 2026-07-28 - Take a Chance on Me: Apply for the Next round of Editorial Fellows.Larissa A Shimoda, Cristina M Alvira, Julie A Bastarache, Rodney D Britt, Rachel S Knipe
American Journal of Physiology. Lung Cellular and Molecular Physiology. 2026-07-18 - 1 citationsLactate transport inhibition therapeutically reprograms fibroblast metabolism in experimental pulmonary fibrosis.David R Ziehr, Fei Li, K Mark Parnell, Nathan M Krah, Kevin J Leahy
Science Translational Medicine. 2026-05-06
Grant Support
- Loss of Endothelial S1PR1 Drives Post-Influenza Pulmonary FibrosisMASSACHUSETTS GENERAL HOSPITAL2023–2028
- Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine ModelARTIAM BIO INC.2025–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









